Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-7

Nothing in life is easy, particularly growing and scaling a kava business. Quarterly has some positives, but it has been a bumpy ride and road ahead is uncertain. Still can't believe the kerfuffle around free options grants, chair leaving, CEO resigning, etc. Such annoying distractions that I hope are behind us.

@SirKnight, suggest fine tuning your new AI horse on "The Australian market... where brand awareness is already high." - my view is that market awareness is still in its infancy in Australia and has a LONG growth runway.

I wonder if e-commerce advertising spend became inefficient Nov/Dec due to US presidential election, Black Friday, Cyber Monday, and Christmas. Seems to me this is the most expensive time of the year to advertise. Might not be a signal that we've maxed out growth in Australian e-commerce.

Does the purchase of the Navua property need to be netted out from the cash balance? If so, cash balance getting lean.

Big growth story this quarter is the shots. 22% of the mix now and growing strongly. Will be very interested to see flavoured shots in the USA and potential for this.

I think we're still looking for our category killer product. We've done our best in Aus where regulations restrict creativity, so it's natural to focus on the US and create something really powerful (strong kavalactone effect, convenient, tastes good).

Hopefully CCO can get on Trump train for a Golden Age in 2025!